Molecular magnetic resonance contrast agents for the detection of cancer: Past and present

Seminars in Oncology

Volumn 38, Issue 1, 2011, Pages 42-54

  Bogdanov Jr , Alexei ^a   Mazzanti, Mary L ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMI 277; CAMPTOTHECIN; CONTRAST MEDIUM; CROSS LINKED IRON OXIDE NANOPARTICLE; CYTOTOXIC AGENT; DNA; ETOPOSIDE; FERUCARBOTRAN; FERUMOXSIL; FERUMOXTRAN 10; FERUMOXYTOL; FLUOROCARBON; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; IRON OXIDE; LIPOCORTIN 5; MAGNETIC NANOPARTICLE; MATRIX METALLOPROTEINASE; MION 47; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOPARTICLE; PACLITAXEL; PENTETIC ACID; POLYASPARTIC ACID; RADIOISOTOPE; RNA; SEROTONIN; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CELL DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; ELECTRON SPIN RESONANCE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IRON DEFICIENCY ANEMIA; LIPOSOMAL DELIVERY; LIVER CANCER; LYMPH NODE METASTASIS; MAGNETISM; MOLECULAR IMAGING; MOLECULAR PROBE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PARTICLE SIZE; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS;

EID: 79952173274     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.11.002     Document Type: Article

References (96)

1. J.M. McKenna New cancer cases will grow 30% by 2020 Economist Intelligence Unit www.eiu.com Aug 28, 2009
2. P. Caravan Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action Acc Chem Res 42 2009 851 862
3. +-based T1 agent is substantially reduced when targeted to a protein microdomain Magn Reson Imaging 26 2008 608 617
4. 3+ complexes Magn Reson Med 2 1985 283 288 (Pubitemid 15057348)
5. P.F. Renshaw, C.S. Owen, A.C. McLaughlin, T.G. Frey, and J.S. Leigh Jr Ferromagnetic contrast agents: a new approach Magn Reson Med 3 1986 217 225 (Pubitemid 16112941)
6. C.F. Geraldes, and S. Laurent Classification and basic properties of contrast agents for magnetic resonance imaging Contrast Media Mol Imaging 4 2009 1 23
7. M.M. Lin, H.H. Kim, H. Kim, J. Dobson, and K. Kim Do Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy Nanomedicine (Lond) 5 2010 109 133
8. D.R. Elias, D.L. Thorek, A.K. Chen, J. Czupryna, and A. Tsourkas In vivo imaging of cancer biomarkers using activatable molecular probes Cancer Biomark 4 2008 287 305
9. G.E. Wesbey, B.L. Engelstad, and R.C. Brasch Paramagnetic pharmaceuticals for magnetic resonance imaging Physiol Chem Phys Med NMR 16 1984 145 155
10. H.M. Jensen, I. Chen, M.R. DeVault, and A.E. Lewis Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer Science 218 1982 293 295 (Pubitemid 12030603)
11. A.P. Pathak Magnetic resonance susceptibility based perfusion imaging of tumors using iron oxide nanoparticles Wiley Interdiscip Rev Nanomed Nanobiotechnol 1 2009 84 97
12. S. Saini, D.D. Stark, P.F. Hahn, J. Wittenberg, T.J. Brady, and J.T. Ferrucci Jr Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system Radiology 162 1987 211 216 (Pubitemid 17001812)
13. S. Saini, D.D. Stark, and P.F. Hahn Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma Radiology 162 1987 217 222 (Pubitemid 17001813)
14. R. Weissleder, P.F. Hahn, and D.D. Stark Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging Radiology 169 1988 399 403
15. X.H. Peng, X. Qian, and H. Mao Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy Int J Nanomed 3 2008 311 321
16. T. Islam, and M.G. Harisinghani Overview of nanoparticle use in cancer imaging Cancer Biomark 5 2009 61 67
17. R. Weissleder, G. Elizondo, and L. Josephson Experimental lymph node metastases: enhanced detection with MR lymphography Radiology 171 1989 835 839 (Pubitemid 19134951)
18. R. Weissleder, G. Elizondo, J. Wittenberg, A.S. Lee, L. Josephson, and T.J. Brady Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging Radiology 175 1990 494 498 (Pubitemid 20135291)
19. Y. Anzai, K.E. Blackwell, and S.L. Hirschowitz Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer Radiology 192 1994 709 715 (Pubitemid 24266786)
20. W.M. Klerkx, L. Bax, and W.B. Veldhuis Detection of lymph node metastases by gadolinium-enhanced magnetic resonance imaging: systematic review and meta-analysis J Natl Cancer Inst 102 2010 244 253
21. O. Will, S. Purkayastha, and C. Chan Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis Lancet Oncol 7 2006 52 60 (Pubitemid 43025393)
22. M.A. Saksena, A. Saokar, and M.G. Harisinghani Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging Eur J Radiol 58 2006 367 374 (Pubitemid 43729065)
23. M.J. Lahaye, S.M. Engelen, and A.G. Kessels USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria Radiology 246 2008 804 811
24. H. Bernd, E. De Kerviler, S. Gaillard, and B. Bonnemain Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program Invest Radiol 44 2009 336 342
25. B. Misselwitz MR contrast agents in lymph node imaging Eur J Radiol 58 2006 375 382 (Pubitemid 43729066)
26. S.M. Moghimi, and B. Bonnemain Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography Adv Drug Deliv Rev 37 1999 295 312 (Pubitemid 29164514)
27. S.H. Choi, M.H. Han, and W.K. Moon Cervical lymph node metastases: MR imaging of gadofluorine M and monocrystalline iron oxide nanoparticle-47 in a rabbit model of head and neck cancer Radiology 241 2006 753 762 (Pubitemid 46190541)
28. C.J. Galban, T.L. Chenevert, and C.R. Meyer The parametric response map is an imaging biomarker for early cancer treatment outcome Nat Med 15 2009 572 576
29. Y. Zong, X. Wang, E.K. Jeong, D.L. Parker, and Z.R. Lu Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents Magn Reson Imaging 27 2009 503 511
30. E.C. Unger, W.G. Totty, and D.M. Neufeld Magnetic resonance imaging using gadolinium labeled monoclonal antibody Invest Radiol 20 1985 693 700 (Pubitemid 16242109)
31. A. Matsumura, Y. Shibata, K. Nakagawa, and T. Nose MRI contrast enhancement by Gd-DTPA-monoclonal antibody in 9L glioma rats Acta Neurochir Suppl (Wien) 60 1994 356 358
32. D. Shahbazi-Gahrouei, M. Williams, S. Rizvi, and B.J. Allen In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma J Magn Reson Imaging 14 2001 169 174 (Pubitemid 32709477)
33. M. Longmire, P.L. Choyke, and H. Kobayashi Dendrimer-based contrast agents for molecular imaging Curr Top Med Chem 8 2008 1180 1186
34. W. Hwang do, H.Y. Ko, and J.H. Lee A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer J Nucl Med 51 2010 98 105
35. A. Bogdanov Jr, L. Matuszewski, C. Bremer, A. Petrovsky, and R. Weissleder Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets Mol Imaging 1 2002 16 23
36. A. Bogdanov, H.W. Kang, and D.G. Bennett Tumor-targeted enzyme mediated MR signal amplification using paramagnetic substrates [abstract] Proc. Intl Soc Magn Reson Med (Meeting Abstracts) 685 2006
37. S. Zhang, M. Merritt, D.E. Woessner, R.E. Lenkinski, and A.D. Sherry PARACEST agents: modulating MRI contrast via water proton exchange Acc Chem Res 36 2003 783 790
38. E. Ruoslahti Specialization of tumour vasculature Nat Rev Cancer 2 2002 83 90 (Pubitemid 37328795)
39. W. Cai, and X. Chen Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism Anticancer Agents Med Chem 6 2006 407 428 (Pubitemid 44377776)
40. D.A. Sipkins, D.A. Cheresh, M.R. Kazemi, L.M. Nevin, M.D. Bednarski, and K.C. Li Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging Nat Med 4 1998 623 626 (Pubitemid 28237365)
41. S.A. Anderson, R.K. Rader, and W.F. Westlin Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles Magn Reson Med 44 2000 433 439
42. M. Lijowski, S. Caruthers, and G. Hu High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model Invest Radiol 44 2009 15 22
43. T. Ke, E.K. Jeong, X. Wang, Y. Feng, D.L. Parker, and Z.R. Lu RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping Int J Nanomed 2 2007 191 199 (Pubitemid 47215020)
44. C. Zhang, M. Jugold, and E.C. Woenne Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner Cancer Res 67 2007 1555 1562 (Pubitemid 46383379)
45. H.Y. Lee, Z. Li, and K. Chen PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles J Nucl Med 49 2008 1371 1379
46. K. Chen, J. Xie, and H. Xu Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting Biomaterials 30 2009 6912 6919
47. H.W. Kang, L. Josephson, A. Petrovsky, R. Weissleder, and A. Bogdanov Jr Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture Bioconjug Chem 13 2002 122 127 (Pubitemid 34119643)
48. H.W. Kang, D. Torres, L. Wald, R. Weissleder, and A.A. Bogdanov Jr Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer Lab Invest 86 2006 599 609 (Pubitemid 43780441)
49. P.R. Reynolds, D.J. Larkman, and D.O. Haskard Detection of vascular expression of E-selectin in vivo with MR imaging Radiology 241 2006 469 476 (Pubitemid 44632893)
50. S. Boutry, S. Laurent, L.V. Elst, and R.N. Muller Specific E-selectin targeting with a superparamagnetic MRI contrast agent Contrast Media Mol Imaging 1 2006 15 22
51. C. Yan, and D.D. Boyd Regulation of matrix metalloproteinase gene expression J Cell Physiol 211 2007 19 26 (Pubitemid 46363892)
52. M. Lepage, W.C. Dow, and M. Melchior Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch Mol Imaging 6 2007 393 403
53. E.S. Olson, T. Jiang, and T.A. Aguilera Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases Proc Natl Acad Sci U S A 107 2010 4311 4316
54. F. Ye, X. Wu, and E.K. Jeong A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI Bioconjug Chem 19 2008 2300 2303
55. M. Tan, X. Wu, E.K. Jeong, Q. Chen, and Z.R. Lu Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging Biomacromolecules 11 2010 754 761
56. E.A. Schellenberger, A. Bogdanov Jr, D. Hogemann, J. Tait, R. Weissleder, and L. Josephson Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI Mol Imaging 1 2002 102 107
57. A.A. Neves, A.S. Krishnan, and M.I. Kettunen A paramagnetic nanoprobe to detect tumor cell death using magnetic resonance imaging Nano Lett 7 2007 1419 1423 (Pubitemid 46834432)
58. M. Zhao, D.A. Beauregard, L. Loizou, B. Davletov, and K.M. Brindle Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent Nat Med 7 2001 1241 1244 (Pubitemid 33063780)
59. H.I. Jung, M.I. Kettunen, B. Davletov, and K.M. Brindle Detection of apoptosis using the C2A domain of synaptotagmin I Bioconjug Chem 15 2004 983 987 (Pubitemid 39297818)
60. G.A. van Tilborg, W.J. Mulder, and N. Deckers Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis Bioconjug Chem 17 2006 741 749 (Pubitemid 43794385)
61. P. Reimer, R. Weissleder, A.S. Lee, J. Wittenberg, and T.J. Brady Receptor imaging: application to MR imaging of liver cancer Radiology 177 1990 729 734
62. R. Weissleder, P. Reimer, A.S. Lee, J. Wittenberg, and T.J. Brady MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors AJR Am J Roentgenol 155 1990 1161 1167
63. R.A. Towner, N. Smith, and Y.A. Tesiram In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging Mol Imaging 6 2007 18 29 (Pubitemid 46642488)
64. P. Reimer, R. Weissleder, T. Shen, W.T. Knoefel, and T.J. Brady Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging Radiology 193 1994 527 531 (Pubitemid 24338345)
65. T.T. Shen, A. Bogdanov Jr, A. Bogdanova, K. Poss, T.J. Brady, and R. Weissleder Magnetically labeled secretin retains receptor affinity to pancreas acinar cells Bioconjug Chem 7 1996 311 316 (Pubitemid 126639663)
66. L. Yang, H. Mao, and Y.A. Wang Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging Small 5 2009 235 243
67. X. Montet, R. Weissleder, and L. Josephson Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas Bioconjug Chem 17 2006 905 911 (Pubitemid 44162607)
68. A. Fleischmann, U. Laderach, H. Friess, M.W. Buechler, and J.C. Reubi Bombesin receptors in distinct tissue compartments of human pancreatic diseases Lab Invest 80 2000 1807 1817 (Pubitemid 32012750)
69. S. Heckl, R. Pipkorn, and W. Waldeck Intracellular visualization of prostate cancer using magnetic resonance imaging Cancer Res 63 2003 4766 4772 (Pubitemid 37022602)
70. S.D. Konda, M. Aref, S. Wang, M. Brechbiel, and E.C. Wiener Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts MAGMA 12 2001 104 113 (Pubitemid 32510128)
71. M. Kresse, S. Wagner, D. Pfefferer, R. Lawaczeck, V. Elste, and W. Semmler Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways Magn Reson Med 40 1998 236 242 (Pubitemid 28361526)
72. D. Hogemann-Savellano, E. Bos, and C. Blondet The transferrin receptor: a potential molecular imaging marker for human cancer Neoplasia 5 2003 495 506 (Pubitemid 38045087)
73. K.A. O'Donnell, D. Yu, and K.I. Zeller Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis Mol Cell Biol 26 2006 2373 2386 (Pubitemid 43346936)
74. D. Artemov, N. Mori, R. Ravi, and Z.M. Bhujwalla Magnetic resonance molecular imaging of the HER-2/neu receptor Cancer Res 63 2003 2723 2727 (Pubitemid 36667139)
75. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
76. Y.M. Huh, Y.W. Jun, and H.T. Song In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals J Am Chem Soc 127 2005 12387 12391
77. J.H. Lee, Y.M. Huh, and Y.W. Jun Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging Nat Med 13 2007 95 99
78. T.J. Chen, T.H. Cheng, and C.Y. Chen Targeted herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI J Biol Inorg Chem 14 2009 253 260
79. C. Leuschner, C.S. Kumar, W. Hansel, W. Soboyejo, J. Zhou, and J. Hormes LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases Breast Cancer Res Treat 99 2006 163 176 (Pubitemid 44268264)
80. L. Yang, X.H. Peng, and Y.A. Wang Receptor-targeted nanoparticles for in vivo imaging of breast cancer Clin Cancer Res 15 2009 4722 4732
81. X. Li, X. Du, T. Huo, X. Liu, S. Zhang, and F. Yuan Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner Acta Radiol 50 2009 583 594
82. O. Veiseh, C. Sun, and C. Fang Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier Cancer Res 69 2009 6200 6207
83. A. Bogdanov Jr, M. DeLeo, M. Shazeeb, H.W. Kang, and C. Sotak Anti-EGF receptor antibody conjugates in MR imaging of human glioma xenografts using enzyme-mediated signal amplification [abstract] Proc 100th AACR Annual Meeting, (Meeting Abstracts) 3219 2009
84. A. Bogdanov Jr, M. DeLeo, M. Shazeeb, H.W. Kang, and C. Sotak Paramagnetic substrate for molecular MR Imaging of EGF receptor in human glioma model using targeted antibody-conjugated enzymatic system [abstract] Proc World Mol Imag Congr (Meeting Abstracts) 1781 2008
85. A. Bogdanov, M. Querol Sans, H.W. Kang, D.G. Bennett, and C. Sotak EGF receptor expression imaging using antibody-conjugated enzymes and a paramagnetic substrate [abstract] Proc Intl Soc Magn Reson Med (Meeting Abstracts) 875 2007
86. A. Bogdanov Jr, H.W. Kang, M. Querol, P.H. Pretorius, and A. Yudina Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo Bioconjug Chem 18 2007 1123 1130 (Pubitemid 47122633)
87. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 2009 874 885
88. A. Moore, Z. Medarova, A. Potthast, and G. Dai In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe Cancer Res 64 2004 1821 1827 (Pubitemid 38428707)
89. Z. Medarova, L. Rashkovetsky, P. Pantazopoulos, and A. Moore Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging Cancer Res 69 2009 1182 1189
90. H. Choi, S.R. Choi, R. Zhou, H.F. Kung, and I.W. Chen Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery Acad Radiol 11 2004 996 1004 (Pubitemid 39220809)
91. R. Weissleder, K. Kelly, E.Y. Sun, T. Shtatland, and L. Josephson Cell-specific targeting of nanoparticles by multivalent attachment of small molecules Nat Biotechnol 23 2005 1418 1423 (Pubitemid 41679395)
92. J.H. Lee, Y.M. Huh, and Y.W. Jun Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging Nat Med 13 2007 95 99
93. J.H. Lee, S.P. Sherlock, and M. Terashima High-contrast in vivo visualization of microvessels using novel FeCo/GC magnetic nanocrystals Magn Reson Med 62 2009 1497 1509
94. M. Das, D. Mishra, and P. Dhak Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging Small 5 2009 2883 2893
95. T.K. Jain, J. Richey, M. Strand, D.L. Leslie-Pelecky, and V. Labhasetwar Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging Biomaterials 29 2008 4012 4021
96. M. Rahimi, A. Wadajkar, and K. Subramanian In vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled drug delivery Nanomedicine 6 2010 672 680